Company / Free Cash Flow
Acadia Pharmaceuticals Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$105.1M
FY2025
5-year range
-$126.8M / $157.2M
FY2021-FY2025
Trend
-33.1%
vs FY2024
Sector context
#46 of 194
Health Care
What the data says
Acadia Pharmaceuticals's free cash flow of $105M is higher than 76% of companies in the Health Care sector (FY2025). Improved from $17M to $105M over the past 2 years.
Based on SEC 10-K filings.
$105M in FY2025. Top quartile in the Health Care sector.
Improved from $17M to $105M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 194This company $105.1M Sector average $470.8M
▼
-77.7% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 33.1% year-over-year.
- Ranks #46 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2024.
- Lowest free cash flow in the period was in FY2017.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $105.1M | -33.1% |
| FY2024 | $157.2M | +844.0% |
| FY2023 | $16.7M | +114.6% |
| FY2022 | -$114.0M | +10.1% |
| FY2021 | -$126.8M | +11.8% |
| FY2020 | -$143.8M | +5.6% |
| FY2019 | -$152.3M | +10.2% |
| FY2018 | -$169.6M | +22.4% |
| FY2017 | -$218.6M | -4.1% |
| FY2016 | -$209.9M | -69.4% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026